- Home
- ESP vs CUE Comparison
ESP vs CUE Comparison
Compare ESP & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESP | CUE |
|---|---|---|
| Founded | 1928 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.8M | 49.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ESP | CUE |
|---|---|---|
| Price | $46.72 | $0.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 14.9K | ★ 1.5M |
| Earning Date | 02-11-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | ★ 28.72 | N/A |
| EPS | ★ 3.16 | N/A |
| Revenue | ★ $42,600,530.00 | $7,100,000.00 |
| Revenue This Year | $9.16 | N/A |
| Revenue Next Year | $5.68 | $25.00 |
| P/E Ratio | $14.83 | ★ N/A |
| Revenue Growth | ★ 4.90 | N/A |
| 52 Week Low | $24.85 | $0.23 |
| 52 Week High | $55.00 | $1.75 |
Technical Indicators
Market Signals| Indicator | ESP | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 66.01 | 39.25 |
| Support Level | $46.27 | $0.23 |
| Resistance Level | $47.77 | $0.33 |
| Average True Range (ATR) | 1.37 | 0.05 |
| MACD | 0.19 | 0.00 |
| Stochastic Oscillator | 81.68 | 39.65 |
Price Performance
Historical ComparisonAbout ESP Espey Mfg. & Electronics Corp.
Espey Manufacturing & Electronics Corp designs, develops, tests, and manufactures specialized military and rugged industrial power supplies and transformers for use in harsh or severe environment applications. Its products and solutions include power converters, power conditioning, high-voltage radar, contract manufacturing, custom engineering, and others. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.